Study of tislelizumab immunotherapy in patients with liver cancer (hepatocellular carcinoma) who have moderately impaired liver function (Child-Pugh B)

Registered drugNo placebo

Study of tislelizumab immunotherapy in patients with liver cancer (hepatocellular carcinoma) who have moderately impaired liver function (Child-Pugh B)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tislelizumab
Sponsor:Unicancer

Contact Research Centre

Neoplasm malignant+1

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Pfizer Inc.

Contact Research Centre

Uveitis+1

Recruiting

Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease

Registered drugNo placebo

Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Study on Continuing or Stopping Imatinib in Patients with Advanced or Metastatic Gastrointestinal Stromal Tumors After 10 Years of Treatment

Registered drugNo placebo

Study on Continuing or Stopping Imatinib in Patients with Advanced or Metastatic Gastrointestinal Stromal Tumors After 10 Years of Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Centre Leon Berard

Contact Research Centre

Angelman's syndrome

Recruiting

Study on the Safety and Effects of ION582 for Patients with Angelman Syndrome

InvestigationalNo placebo

Study on the Safety and Effects of ION582 for Patients with Angelman Syndrome

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years
Sponsor:Ionis Pharmaceuticals Inc.

Contact Research Centre

Asthma

Recruiting

Study on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment

Registered drugNo placebo

Study on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Omalizumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Colorectal cancer metastatic+2

Recruiting

Study on the Effects of Atezolizumab, Bevacizumab, Oxaliplatin, and Capecitabine in Patients with Colorectal Cancer and Liver Metastasis

Registered drugNo placebo

Study on the Effects of Atezolizumab, Bevacizumab, Oxaliplatin, and Capecitabine in Patients with Colorectal Cancer and Liver Metastasis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Parkinson's disease

Recruiting

Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson's Disease Patients

Registered drug

Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson's Disease Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Amantadine Hydrochloride
Sponsor:Centre Hospitalier Universitaire De Toulouse

Contact Research Centre

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:OSE Immunotherapeutics

Contact Research Centre

Primary biliary cholangitis

Recruiting

Study on Bezafibrate for Patients with Primary Biliary Cholangitis Not Responding Well to Ursodeoxycholic Acid

Registered drug

Study on Bezafibrate for Patients with Primary Biliary Cholangitis Not Responding Well to Ursodeoxycholic Acid

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Bezafibrate
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Clichy

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative trials focusing on inflammatory bowel diseases and advanced treatment methods, including studies on Crohn's disease and ulcerative colitis using fecal microbiota transplantation as therapeutic approaches.

Crohn's Disease Management
Ulcerative Colitis Treatment
Short Bowel Syndrome

Research aims to improve patient outcomes through novel therapeutic interventions and treatment strategies.

02 Hepatobiliary Research

Comprehensive studies on liver diseases and biliary tract conditions, investigating new treatments for cirrhosis, portal hypertension, and various forms of liver cancer.

Hepatocellular Carcinoma
Biliary Tract Cancer
Liver Cirrhosis

Advanced therapeutic approaches combining immunotherapy and targeted treatments.

03 Pancreatic and Metabolic Disorders

Groundbreaking research on pancreatic cancer and metabolic conditions, evaluating novel drug combinations and treatment protocols.

Pancreatic Adenocarcinoma
Neuroendocrine Tumors
Metabolic Liver Disease

Focus on improving survival rates and treatment efficacy in advanced-stage diseases.

Back to France All countries